Literature DB >> 15871113

Seroprevalence of human papillomavirus type 16 in children.

Eileen F Dunne1, Kevin L Karem, Maya R Sternberg, Katherine M Stone, Elizabeth R Unger, William C Reeves, Lauri E Markowitz.   

Abstract

We evaluated the prevalence of antibodies to human papillomavirus (HPV) type 16 in a representative sample of children 6-11 years of age in the United States. Serum samples and questionnaire data were collected between 1991 and 1994, for the National Health and Nutrition Examination Survey III. HPV-16-specific immunoglobulin G antibodies were detected by an HPV-16 L1 virus-like particle-based enzyme-linked immunosorbant assay. Overall, 2.4% of 1316 children 6-11 years of age were seropositive. Seroprevalence was higher in boys than in girls (3.5% vs. 1.2%; P=.08) and in children >7 years of age than in children < or =7 years of age (3.3% vs. 0.4%; P<.05). None of the variables tested for, including race/ethnicity, socioeconomic status, and urban or rural residence, were significantly associated with HPV-16 seropositivity. To explain HPV-16 seropositivity in this population, further study is required.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15871113     DOI: 10.1086/430274

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Review of Gardasil.

Authors:  Diane M Harper; Stephen L Vierthaler; Jennifer A Santee
Journal:  J Vaccines Vaccin       Date:  2010-11-23

Review 2.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

3.  Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia.

Authors:  Parinda A Mehta; Sharon Sauter; Xue Zhang; Stella M Davies; Suzanne I Wells; Kasiani C Myers; Gitika Panicker; Elizabeth R Unger; Melinda Butsch Kovacic
Journal:  Vaccine       Date:  2017-10-16       Impact factor: 3.641

4.  Detection of antibodies against epidermodysplasia verruciformis-associated canine papillomavirus 3 in sera of dogs from Europe and Africa by enzyme-linked immunosorbent assay.

Authors:  C E Lange; K Tobler; C Favrot; M Müller; J O Nöthling; M Ackermann
Journal:  Clin Vaccine Immunol       Date:  2008-11-26

5.  Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic.

Authors:  Eva Hamsikova; Viera Ludvikova; Jana Stasikova; Ruth Tachezy
Journal:  Sex Transm Infect       Date:  2012-06-08       Impact factor: 3.519

6.  Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.

Authors:  Diane M Harper; Stephen L Vierthaler
Journal:  ISRN Obstet Gynecol       Date:  2011-11-02

7.  Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany.

Authors:  Anna Loenenbach; Michael Pawlita; Tim Waterboer; Thomas Harder; Christina Poethko-Müller; Michael Thamm; Raskit Lachmann; Yvonne Deleré; Ole Wichmann; Miriam Wiese-Posselt
Journal:  BMC Infect Dis       Date:  2022-01-10       Impact factor: 3.090

8.  Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases.

Authors:  Luciano Mariani; Sonia Pagliusi
Journal:  J Exp Clin Cancer Res       Date:  2008-12-16

9.  Seroprevalence of 34 human papillomavirus types in the German general population.

Authors:  Kristina M Michael; Tim Waterboer; Peter Sehr; Annette Rother; Ulrich Reidel; Heiner Boeing; Ignacio G Bravo; Jörg Schlehofer; Barbara C Gärtner; Michael Pawlita
Journal:  PLoS Pathog       Date:  2008-06-20       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.